期刊文献+

PTD-OD-HA融合蛋白对K562细胞中Bcr-Abl的抑制作用观察

Inhibitory effect of PTD-OD-HA fusion protein on Bcr-Abl in K562 cells
下载PDF
导出
摘要 目的探讨PTD-OD-HA融合蛋白转导K562细胞的动力学、定位及其与Bcr-Abl定位的关系,以及对Bcr-Abl寡聚化和Bcr-Abl酪氨酸激酶活性的影响。方法采用FITC标记PTD-OD-HA融合蛋白,观察蛋白转导K562细胞的效率与剂量和时间的关系,激光共聚焦显微镜检测融合蛋白在细胞内的定位,免疫共沉淀法检测融合蛋白与Bcr-Abl的相互作用,Western blotting检测Bcr-Abl的磷酸化水平。结果 PTD-OD-HA转导K562细胞呈剂量和时间依赖性。PTD-OD-HA定位于K562细胞胞质,与Bcr-Abl共定位,且能与Bcr-Abl蛋白相互作用,进而干扰Bcr-Abl同源寡聚化,并可降低Bcr-Abl的磷酸化水平。结论在K562细胞中,PTD-OD-HA融合蛋白能有效抑制Bcr-Abl同源寡聚化及磷酸化水平。 Objective To study the transduction dynamics, location of PTD-OD-HA fusion protein and its interaction with Bcr-Abl oncoprotein in K562 cell lines, and explore the influence of PTD-OD-HA fusion protein on oligomerization and tyrosine kinase activity of Bcr-Abl. Methods PTD-OD-HA fusion protein was labeled with FITC and co-cultured with K562 cells. The transduction efficiency of labeled PTD-OD-HA at different doses and time intervals was observed under fluorescence microscope. The location oflabeled PTD-OD-HA fusion protein in K562 cells was detected by confocal microscopy. The interaction of PTD-OD-HA fusion protein with Bcr-Abl oncoprotein was confirmed by coimmunoprecipitation. The phosphorylation of Bcr- Abl oncoprotein was detected by Western blotting. Results PTD-OD-HA fusion protein labeled with FITC was transduced into K562 cells in a dose- and time-dependent manner. PTD-OD-HA fusion protein was located in the cytoplasm of K562 cells and was consistent with the location of Bcr-Abl oncoprotein. The interaction of PTD-OD-HA fusion protein with Bcr-Abl oncoprotein was proved in K562 cells. This interaction could interrupt the homologous oligomerization of Bcr-Abl oncoprotein and reduce the phosphorylation of Bcr-Abl oncoprotein. Conclusion PTD-OD-HA fusion protein could be transduced into K562 cells efficiently, inhibiting the oligomerization and reducing the phosphorylation of Bcr-Abl oncoprotein.
出处 《解放军医学杂志》 CAS CSCD 北大核心 2012年第10期951-954,共4页 Medical Journal of Chinese People's Liberation Army
基金 国家自然科学基金(30670901)~~
关键词 白血病 髓样 慢性 蛋白转导域 融合蛋白质类 bcr-abl leukemia, myeloid, chronic protein transduction domain fusion proteins, bcr-abl
  • 相关文献

参考文献7

  • 1Lugo T, Pendergast A, Muller A, et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products[J]. Science, 1990, 247(4946): 1079-1082.
  • 2Epstein FH, Faderl S, Talpaz M, et al. The biology of chronic myeloid leukemia . New EnglJ Med, 1999, 341(3): 164-172.
  • 3Zhao X, Ghaffari S, Lodish H, et al. Structure of the Bcr-Abl oncoprotein oligomerization domain[J]. Nat Struct Mol Biol, 2002, 9(2): 117-120.
  • 4Beissert T, Puccetti E, Bianchini A, et al. Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571 [J]. Blood, 2003, 102(8): 2985- 2993.
  • 5Ghaffari S, Wu H, Gerlach M, et al. BCR-ABL and v-SRC tyrosine kinase oncoproteins support normal erythroid development in erythropoietin receptor-deficient progenitor cells[J]. Proc Nat Acad Sci USA, 1999, 96(23): 13186-13190.
  • 6Gugliotta G, Castagnetti F, Palandri F, et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party[J]. Blood, 2011, 117(21): 5591-5599.
  • 7Efficace F, Baccarani M, Breccia M, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population[J]. Blood, 2011, 118(17): 4554-4560.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部